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Brain deposition of the amyloid beta-protein (A𝗽) and tau are characteristic features in Alzheimer’s disease (AD). Mutations in the
A𝗽 precursor protein (APP) and a protease involved in A𝗽 production from APP strongly argue for a pathogenic role of A𝗽 in AD,
while mutations in tau are associated with related disorders collectively called frontotemporal lobar degeneration (FTLD). Despite
intense effort, therapeutic strategies that target A𝗽 or tau have not yet yielded medications, suggesting that alternative approaches
should be pursued. In recent years, our laboratory has studied the role of mRNA in AD and FTLD, specifically those encoding tau
and the A𝗽-producing protease BACE1. As many FTLD-causing tau mutations destabilize a hairpin structure that regulates RNA
splicing,wehavetargetedthisstructurewithsmallmolecules,antisenseoligonucleotides,andsmallmolecule-antisenseconjugates.
We have also discovered that microRNA interaction with the 3
򸀠-untranslated region of tau regulates tau expression. Regarding
BACE1, we found that alternative splicing leads to inactive splice isoforms and antisense oligonucleotides shift splicing toward
these inactive isoforms to decrease A𝗽 production. In addition, a G-quadruplex structure in the BACE1 mRNA plays a role in
splice regulation. The prospects for targeting tau and BACE1 mRNAs as therapeutic strategies will be discussed.
1. Introduction
1.1.ProteinAggregationinAlzheimer’sandRelatedDementias.
Aberrant protein deposition is a common characteristic of
neurodegenerative diseases, including Alzheimer’s disease
(AD), frontotemporal lobar degeneration (FTLD), Parkin-
son’sdisease,amyotrophiclateralsclerosis,andpriondiseases
[1]. In AD, two pathological features define the disease:
amyloid plaques and neurofibrillary tangles [2]. Amyloid
plaques are extraneuronal deposits primarily composed of
the amyloid 𝗽-protein (A𝗽), while neurofibrillary tangles
are intraneuronal filaments composed of the otherwise
microtubule-associated protein tau. These two pathological
deposits were first described over a century ago by Alois
Alzheimerhimselfincharacterizingthediseasethatbearshis
name. The question of whether either of these proteinaceous
deposits is involved in disease etiology or coincidental mark-
ers has been much debated and still remains unresolved.
W h i l et h er o l eo ft h ed e p o s i t sper se in the pathogenesis
of AD is unclear, evidence strongly implicates the A𝗽 and
tau proteins as key components in the neurodegenerative
pathway(s). The A𝗽 precursor protein (APP) undergoes
sequential proteolysis by 𝗽-secretase and 𝗾-secretase to
produce A𝗽, a 4kDa amphipathic protein prone to aggre-
gation [3]. Dominant missense mutations in and around
the A𝗽 region of APP or in the catalytic component of 𝗾-
secretase(presenilin)areassociatedwithearlyonset(<age60
years) AD, and these mutations change the type or amount
of A𝗽 to increase its tendency to aggregate. In recent years,
considerable evidence has supported the hypothesis that
soluble oligomeric forms of A𝗽 are particularly responsible
for inhibiting proper synapse function and are toxic to
neurons, although this hypothesis is still controversial [4].
While the amyloid plaques appear to be less detrimental,
they may serve as a reservoir for soluble A𝗽 oligomers
[5].
Tau is a 50–70kDa microtubule-associated protein found
in high levels in neurons, particularly in axons, and appears
to function in microtubule formation, stability, and dynam-
ics [6, 7]. The C-terminal region of tau is composed of
3 or 4 imperfectly repeated microtubule binding domains
(Figure 1), but regions outside the repeat domains are also
involved in microtubule binding [8–10]. In AD, tau becomes
dissociated from microtubules, mislocalizes to neuronal cell
bodies and dendrites, becomes hyperphosphorylated, and
assembles into filaments [11]. These filaments comprise the
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Figure1:Tauspliceisoforms,mutations,andsplicing.(a)Alternativesplicingofexon10resultsintauisoformswitheither3or4microtubule-
binding repeat domains (3R or 4R tau). Alternative splicing of exons 2 and 3 is not shown. Site of FTLD-associated exonic mutations is
indicated. Some of these mutations are silent and/or alter exon 10 splicing (red). Some of these mutations are also specific for the 4R isoforms
of tau (bracket). (b) Stem-loop structure at the junction between exon 10 and intron 10. Site of FTLD-associated mutations in this structure
destabilizing the stem-loop, increasing access to splicing factors and exon 10 inclusion, and resulting in increased 4R over 3R tau isoforms.
neurofibrillary tangles described by Alzheimer that appear
darkly upon silver staining. Genetic evidence in animals
supportsanessentialroleoftauintheA𝗽-drivendementiaof
AD: knockout of the tau gene rescues learning and memory
deficitsinAPPtransgenicADmousemodels[12],aresultthat
suggests that reduction of tau protein may be therapeutic for
AD. Although mutations in tau are not associated with AD,
tau-positive neurofibrillary tangles spatially correlate better
with neurodegeneration than does A𝗽,a g a i ns u g g e s t i n g
that aberrant tau is downstream of A𝗽 and more proximal
to neuronal cell death. In recent years, gathering evidence
supports a model in which pathological tau is transmitted
synaptically from neuron to neuron [13–15].
FTLD refers to the pathological situation in which the
frontal and temporal lobes of the brain degenerate [16, 17]. In
this pathology, different protein inclusions can be observed,
including TAR DNA-binding protein 43 (TDP-43), fused-in-
sarcoma (FUS), and tau. Clinically, these pathologies may
manifest as Pick’s disease, progressive nuclear palsy (PSP),
corticobasal degeneration (CBD), argyrophilic grain disease
(AGD), tangle-only dementia, and frontotemporal dementia
with Parkinsonism linked to chromosome 17 (FTD-17).
DominantmutationsintaucauseFTLD[18–20],notAD,but
thepresenceofsimilartaupathologyinthissubtypeofFTLD
(FTLD-tau) suggests that aberrant tau is also pathogenic
in AD and that a variety of neuronal insults, includingScientifica 3
assembled forms of A𝗽, can trigger changes in tau that
ultimately lead to pathological deposition. FTLD mutations
in tau result in microtubule dissociation, hyperphospho-
rylation, neuronal mislocalization, filament formation, and
neurofibrillary tangles [16], the same molecular events that
o c c u ri nA D .Th u s ,u n d e r s t a n d i n gt h er o l eo fa b e r r a n tt a ui n
FTLD-tau pathogenesis should be highly relevant to the role
of tau in AD. Taken together, evidence strongly suggests that
lowering tau levels is a worthwhile therapeutic goal for both
ADandFTLD-ta u.F o rAD ,whiletargetingA𝗽isexpectedto
atleastpreventdiseaseonset,ifnotprogression,targetingtau
is more likely to slow or stop disease progression.
1.2. Targeting mRNA as an Alternative Therapeutic Strategy.
A variety of approaches have been taken toward targeting
the A𝗽 and tau proteins over the years. For A𝗽,p e r h a p s
the leading strategy has been the inhibition of the proteases
responsible for its production from APP, 𝗽-secretase (also
called𝗽-siteAPPcleavingenzyme1orBACE1),amembrane-
tethered aspartyl protease related to pepsin [21], and 𝗾-
secretase, a membrane-embedded protease complex [22].
Much previous experience in the pharmaceutical industry
with structure-based design of aspartyl protease inhibitors
as drugs (e.g., HIV protease inhibitors, renin inhibitors)
developing BACE1 inhibitors with appropriate CNS drug-
like properties has been difficult [23], due to the long,
shallow nature of the enzyme’s active site and the tendency of
many BACE1 inhibitors to be exported from the brain by P-
glycoprotein. While these hurdles are being slowly overcome
and several BACE1 inhibitors are in clinical trials, there is
still enough concern to warrant consideration of alternative
approaches to targeting BACE1.
𝗾-Secretase is also an aspartyl protease, although it is a
complex of four integral membrane proteins and completely
unrelated to soluble or membrane-tethered proteases [24].
Nevertheless, inhibitors of 𝗾-secretase were more easily
identified and several of these advanced into the clinic
much more quickly than inhibitors of BACE1. However, 𝗾-
secretase cleaves other proteins besides APP, and some of
these serve essential cell signaling roles in human biology
[25]. For this reason, 𝗾-secretase inhibitors have displayed
mechanism-based toxicities that preclude approval for use
in AD [26]. Currently, modulation of 𝗾-secretase activity to
reduce forms of A𝗽 that are particularly aggregation prone is
the leading strategy for targeting this enzyme [26]. Another
major approach to target A𝗽 is immunotherapy with anti-A𝗽
antibodies [27]. To some degree, these antibodies can access
the brain and clear out neurotoxic A𝗽.A l t h o u g hs e v e r a lo f
t h e s eh a v ea d v a n c e dt h r o u g hc l i n i c a lt r i a l s ,e ffi c a c yh a sb e e n
equivocal at best [28, 29].
Toward targeting tau, the major approach has been
to develop inhibitors of kinases thought to be important
in forming the hyperphosphorylated forms of the protein
associatedwithtaufilamentsandneurofibrillarytangles[30].
While tau is phosphorylated at many of its Ser, Thr, and
Tyr residues and a variety of kinases have been implicated
in phosphorylating these sites, several sites are particularly
associated with pathological tau, and certain kinases are
reasonable candidates for phosphorylating these specific
sites [31]. These include CDK5, GSK3, and MARK. While
inhibitors of these kinases have been developed, potency,
specificity, and brain penetration are often issues and few if
any have advanced into clinical trials. Moreover, questions
remain about the importance of any particular kinase, or
even if tau hyperphosphorylation is pathogenic or merely
coincidental, raising concerns that improving the properties
of the drugs may not result in efficacy.
Thus to date all clinical trials for AD therapeutics have
failed to progress to approved drugs. While the reasons for
these failures vary depending on the specific agent and the
approach, collectively these discouraging results suggest that
alternative strategies should be pursued, at least in parallel.
Toward that end, in recent years our laboratory has focused
on mRNA relevant to AD and related dementias as potential
targets.Thisapproachseemsparticularlyappropriateincases
where the protein target is not considered “druggable,” with
tau being a prime example. In general, the mRNA encoding
t h ep a t h o g e n i cp r o t e i no re n z y m ec a nb et a r g e t e ds oa st o
shiftalternativesplicingtowardlesstoxicorinactiveformsor
k n o c k e dd o w nt os i m p l yr e d u c ea l lf o r m so ft h ep r o t e i n .T a r -
getingthemRNAmaybeaccomplishedwithsmallmolecules
(where structure is present in the relevant region of the
mRNA), with antisense oligonucleotides (ASOs), with small
interfering RNA (siRNA), or with microRNA (miRNA). For
A Da n dF T L D - t a u ,w eh a v ef o c u s e do nm R N Ae n c o d i n g
tau and BACE1 as potential targets and described these
approaches below.
2. Tau mRNA
2.1. Disease-Causing Mutations Alter Tau mRNA Splicing.
Nearly 40 mutations associated with FTLD-tau have been
identified [32]. These are all either missense mutations,
mutations that affect splicing, or both, and almost all cluster
in the portion encoding the C-terminal region or in an
intervening sequence near exon 10 (Figure 1(a)). The C-
terminalmissensemutationsallappeartoimpairtaubinding
tomicrotubulesandtheabilityoftautopromotemicrotubule
assembly. Most of the silent mutations increase the 4R-to-3R
ratio by modulating alternative splicing of exon 10. Missense
mutations found within exon 10 only affect the 4R isoforms
(Figure 1), while those found outside this region affect all
six tau isoforms. Along with the consistent tau deposition
i nt h e s ef a m i l i a lc a s e sa n dt h eo b s e r v a t i o nt h a tc o m p l e t e
knockout of tau in mice does not lead to neurodegeneration,
t h ef a c tt h a ta l lb u to n eo ft h ed i s e a s e - a s s o c i a t e dm u t a t i o n s
[33]aredominantstronglysuggestsagainofatoxicfunction:
onenormalcopyremains,and,inthecaseofexon10missense
mutations, even the 3R tau isoforms translated from the
d i s e a s ea l l e l ea r en o r m a l .N od i s e a s e - a s s o c i a t e dm u t a t i o n s
have been identified that lead to either a truncated protein
or the nonsense-mediated decay of message.
Most of the silent and intronic mutations near the
exon 10 5
򸀠 splice site enhance exon 10 inclusion and desta-
bilize a stem-loop structure at the exon-intron junction
(Figure 1(b)). The stem-loop structure was hypothesized [18,
19, 34] upon the initial discovery of FTLD-tau mutations
in the tau gene, noting the apparent self-complementarity4 Scientifica
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Figure 2: (a) Mitoxantrone structure (MTX). (b) NMR solution structure of MTX (yellow) bound to the tau RNA stem-loop. The aromatic
region is intercalated between two G-C base pairs and flanking an unpaired adenosine. Side chains lie along the major groove.
in this region. Subsequent determination of the solution
s t r u c t u r eo fa no l i g o n u c l e o t i d eb a s e do nt h i se x o n - i n t r o n
junction by nuclear magnetic resonance spectroscopy [35]
led to refinement of the stem-loop model to seven specific
base pairs (Figure 1(b)) with an adenosine bulge between the
s i x t ha n ds e v e n t hb a s ep a i r .Th es t r u c t u r ef u r t h e rs h o w st h a t
this unpaired purine ring is intercalated back into the A-
form RNA duplex. Disease-associated mutations found in
this region would be predicted to destabilize the stem-loop
and make this site more available to splicing factors (specif-
ically the U1 snRNP that interacts with the 5
򸀠 splice site).
Thermal stability studies of oligonucleotides demonstrated
that disease-associated mutations within the putative stem-
loop lower the melting temperature of the RNA duplex (i.e.,
where the double-stranded RNA dissociates with the single-
stranded form) [35, 36]. A minigene construct encoding
exons 9–11 recapitulates normal tau exon 10 splicing for
the wild-type sequence and increased exon 10 inclusion for
disease-causing mutations [37]. This minigene has been used
in our lab to demonstrate that other mutations specifically
designed to enhance stability of the stem-loop (and located
distal to the U1 snRNP binding site) reduce exon 10 inclusion
to decrease 4R/3R as predicted [36], validating the stem-loop
as a bona fide structure involved in the regulation of tau
exon 10 splicing and worthy of consideration as a therapeutic
target.
2.2. Targeting Tau Exon 10 Splicing with Small Molecules [38–
40]. Havingvalidatedthetaustem-loopRNAasasignificant
regulatory element in controlling tau mRNA splicing, we
designedahigh-throughputscreentoidentifysmallmolecule
ligands of the stem-loop RNA and developed other assays
to validate the results of this screen [38]. Such compounds
should stabilize the stem-loop and lower the 4R-to-3R ratio
( i . e . ,d ot h eo p p o s i t eo fd i s e a s e - c a u s i n gm u t a t i o n s ) .Th i s
a p p r o a c hm a yl e a dt on e wt h e r a p e u t i ca g e n t sf o rn o to n l y
familial FTLD-tau with tau mutations but also all forms
of FTLD-tau in which 4R tau isoforms predominate in
neurofibrillarytangles(e.g.,PSPandCBD)[16,41].Moreover,
the possibility remains that shifting the balance of 4R/3R
tau in AD may be beneficial as well. Although evidence for
changes in tau RNA splicing in AD has been equivocal [42,
43],the4Risoformsmaybemorepronetoaggregateandseed
coaggregation with 3R tau isoforms, as the repeat domains
can transition from random coil to 𝗽-sheet conformations
and are sufficient for filament formation [44].
Aminoglycosides are known to bind to double-helical
RNA structures, including an oligonucleotide represent-
ing the tau mRNA stem-loop [45]. Based on the NMR-
determined structure of neomycin bound to the tau stem-
loop [45], we designed and synthesized pyrene-conjugated
aminoglycosidesasfluorescentprobesforscreening.Binding
of the pyrene-aminoglycoside to the stem-loop quenches the
pyrene fluorescence through intercalation. Thus, compounds
that compete with such probes for stem-loop binding would
increase levels of unbound probe and increase fluores-
cence. This approach was first validated with unconjugated
aminoglycosides, demonstrating concentration-dependent
increases in fluorescence, and then miniaturized for auto-
mated screening of 130,000 drug-like compounds. Though a
number of compounds were identified as possible hits in this
assay, only one passed secondary and tertiary biochemical
tests: the anticancer drug mitoxantrone (MTX, Figure 2).
The NMR solution structure of the tau mRNA-MTX
complex [39] revealed that MTX binds in a region near
t h eb a s eo ft h es t e m ,a tt h es i t eo ft h eu n p a i r e da d e n o -
sine (Figure 2). The aromatic ring system of the compound
intercalates between two stacked G-C base pairs, and the
side chains of the compound bind in the major groove
via a combination of hydrogen bonding and electrostaticScientifica 5
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Figure 3: MTX analogs that retain or enhance the ability to bind and stabilize the tau RNA stem-loop structure.
interactions.Wethendesignedandsynthesizedaset ofMTX
analogues to explore structure-activity relationships and test
the validity of the NMR-derived MTX-RNA 3-D structure
[40]. We determined that the aromatic core and both side
chains are required for RNA binding comparable to MTX;
neither the side chain alone, the aromatic core alone, nor
t h ea r o m a t i cc o r ew i t ho n l yo n es i d ec h a i nb i n dw e l l ,i fa t
all. However, conversion of one or two of the terminal side
chainhydroxylstoamine(e.g.,1,Figure 3)ledtoasubstantial
increase in binding and stabilization, and extension with
an additional ethylamine (e.g., 2, Figure 3)g a v ec o m p a r a b l e
activities. Moreover, additional side chains (tri- and tetra-
substituted 3 and 4, Figure 3)w e r ew e l lt o l e r a t e d ,g i v i n g
potencies comparable to MTX. These results and those with
otherMTXanalogswereallcompatiblewiththeNMRmodel
of MTX binding to tau RNA.
2.3. Targeting Tau Exon 10 Splicing with Bipartite Antisense
Oligonucleotides [46]. In a complementary strategy to tar-
get the tau hairpin structure, we designed bipartite anti-
sense oligonucleotides (ASOs), composed of two antisense
regions within a single oligonucleotide, with spacer adeno-
sine nucleotides [46]. Our designed bipartite ASOs have up
to 10 bases on either side, complementary to their respective
partner regions that flank the stem-loop, and have 0, 1, 2, or
3 adenosine spacers (Figure 4). The spacer adenosines are to
bridge any potential gap between the flanking sequences due
to the presence of the stem. Adenosine was chosen because
there are no complementary uridines at the base of the stem.
We found that such bipartite ASOs do indeed bind to
the tau pre-mRNA in the regions flanking the stem-loop.
Electrophoretic mobility shift assays (EMSAs) demonstrated
bindingofbipartiteDNAASOscomparableto(orevenbetter
than) a control ASO targeting a linear sequence at the exon-
intron boundary. DNA ASOs shorter than 7 nucleotides on
either side of the linker did not bind, while 8 nucleotides
on either side were sufficient for substantial binding. RNase
protection assays demonstrated that both flanking regions
were occupied by the designed ASOs. Bipartite RNA ASO
counterparts with 2
򸀠-O-methylribose and phosphorothioate
bonds (providing stability in cells) showed similar effects in
EMSA but could also decrease 4R tau mRNA and increase
the 3R tau form from either a tau minigene in SK-N-SH
neuroblastomacellsorendogenoustauinHEK293cells,with
no effect on overall tau mRNA levels.
In addition, we synthesized and tested bipartite peptide-
nucleic acid (PNA) oligos. PNA contains a peptide backbone
with nucleobase substituents, chemically and metabolically
stable oligos that effectively target complementary RNA
sequences and act as antisense molecules (Figure 5(a))[ 47].
The design of PNA molecules targeted to the tau stem-
loop flanking regions is shown in Figure 5(b).T w oc o m -
plementary PNA sequences were linked via 8-amino-3,6-
dioxaoctanoic acid (egl) moieties (9-atom spacers), which
generates a polyethylene glycol-like chain. The egl linker
avoids potential problem of unwanted interactions of the
adenosine linkers described above for bipartite DNA and
RNA ASOs. In addition, a polylysine sequence was added,
as this motif (8 Lys on the C-terminus, 1 Lys on the6 Scientifica
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Figure 5: Bipartite peptide-nucleic acids (PNAs) and tripartite MTX-PNA. (a) General structure of PNA. (b) Designed bipartite PNA
targetingthetauRNAstem-loopstructure.AntisensePNAregionsinpurple;ethyleneglycollinker(egl)ingreen;lysinesaddedforsolubility
and cell penetration in blue.
N-terminus)isreportedtogreatlyenhancePNApermeability
in cells and tissue distribution in vivo [48]. Also, PNA binds
much more strongly to RNA than does a corresponding
DNA or RNA [49]; therefore, the designed length of the two
complementaryPNAregions(ingreeninFigure 5(b))ranges
from 4 to 9 nucleobases on either side. EMSA demonstrated
that 5 nucleobases on either side are sufficient for effective
binding, substantially shorter (by 2–4 bases total) than what
is required for bipartite DNA or RNA ASO binding.
2.4.TowardSmallMolecule-AntisenseConjugates[50]. While
MTX is a small-molecule drug with good physicochemi-
cal and pharmacokinetic properties, major problems with
pursuing MTX to target tau mRNA include its toxicity
and lack of specificity. MTX is an anticancer drug that
inhibits DNA topoisomerase [51], and MTX binds to other
RNA hairpin structures besides that of tau (unpublished
results). Moreover, even with the NMR structure of MTX
boundtothestem-loop[39], structure-based design of MTX
analogs to enhance potency and selectivity will not likely
leadtocompoundswithdramaticallyimprovedproperties,as
similar approaches over the years with other small-molecule
RNA ligands (e.g., neomycin) have not generated dramatic
improvements in potency and, more importantly, specificity
[52]. In contrast to small molecule ligands, the bipartite
ASOs described above have excellent specificity and alter tau
splicing in cells, but these agents do not have good drug-
like properties. We have begun to combine these approaches,
to generate MTX-ASO conjugates, in order to eliminate the
toxicity of MTX, increase specificity, and demonstrate that
such “molecular clasps” can effectively bind the tau stem-
loop and flanking sequences and shift splicing away from the
deleterious 4R isoforms in cells.Scientifica 7
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Figure 6: (a) Schematic of template-directed combinatorial strategy to identify MTX-PNA conjugates. MTX analogs containing a linker-
azide combined bipartite PNA with a linker-alkyne in the presence of tau RNA oligonucleotide representing the stem-loop and flanking
sequences. MTX and PNA analogs that bind well, with the proper distance and orientation between azide and alkyne, undergo cyclization to
a 1,2,3-triazole. (b) MTX conjugated to bipartite PNA identified through template-directed combinatorial chemistry.
We selected PNAs as the initial class of antisense
moleculestocarryoutconjugationtoMTX,asthesebipartite
A S O sb o u n dt ot a uR N Ae v e nw h e ns h o r t e n e dt o5 - 6
nucleobasesoneitherside.ToidentifyPNA-MTXconjugates
c a p a b l eo fb i n d i n gt h et a um R N A ,w ec a r r i e do u tat e m p l a t e -
directed synthesis (Figure 6(a)). A 40-residue RNA oligo
was used as a template to bring together PNA and MTX
fragments with reactive functional groups. Specifically, we
employed the Huisgen 1,3-dipolar cycloaddition reaction
(often referred to as “click chemistry”), which involves tria-
zoleringformationbetweenazideandalkynefunctionalities.
Th i st y p eo fr e a c t i o ni sh i g h l ys p e c i fi ca n dh a se v e nb e e n
accomplished in living mice [53–55]. Previous reports have
described template-directed reactions using enzymes [56–
60] or nucleic acids [61–64] as templates.
Concerning the general design of MTX fragments, we
hadalreadydeterminedthatthechainsontheanthraquinone
ring system can be extended with retention of tau stem-
loop binding (e.g., 2, Figure 3)[ 40]. Two different length
linkers, of 8 and 17 atoms and with azide groups on the
ends, on MTX were synthesized to maximize the chance of
coupling, although both were expected to be capable based
ontheMTX-RNAstructuralmodeldeterminedbyNMR(the
b indin gsi t eisc loset othebaseo fthes t ema ndther ef o r enea r
the flanking sequences where the bipartite antisense probes
bind). We also synthesized linker-extended forms of tri- and
tetra-substituted 3 and 4 (Figure 3), which also effectively
boundtothetaustem-loopstructure[40].ForPNA,wechose
several different linkers joining the two antisense “arms”
which varied in the position of an alkyne substituent for
reaction with the azide on the MTX fragment. Altogether,
six different MTX analogues and ten different PNA oligos
were combined, for a total of 60 different reactions, in the
presence of the tau-based RNA oligo. Only one of these
combinations led to successful template-directed coupling,
providing compound 16 (Figure 6(b))a st h efi r s tc a n d i d a t e
molecular clasp. This compound was capable of binding
the tau-based oligonucleotide and inhibited tau splicing in
vitro better than the bipartite PNA alone. However, the
compound still proved too cytotoxic to demonstrate effects8 Scientifica
on tau splicing in cells. Means to improve this prototype
compound include replacing MTX with an RNA stem-loop
binding compound that is nontoxic.
2.5. Regulation of Tau mRNA via Its 3
򸀠-Untranslated Region
[65]. As another means of targeting tau mRNA, we consid-
ered its 3
򸀠-untranslated region (3
򸀠-UTR). In general, 3
򸀠-UTR
has a variety of functions in regulating gene expression, such
as 3
򸀠-end processing, translational regulation, stability, and
subcellular localization of the transcript [66]. These regu-
latory roles are mediated by the interaction of cis-elements
in the 3
򸀠-UTR and trans-factors, which include proteins
and microRNAs (miRNAs), in the cell [67]. An additional
level of regulation results from alternative polyadenylation,
which can occur in transcripts that contain two or more
polyadenylation signals. Transcripts that undergo alternative
polyadenylation express alternative 3
򸀠-UTR isoforms, which
can be differentially regulated by either the inclusion or
exclusion of regulatory cis-elements [68]. The human tau 3
򸀠-
UTR,aswellasthatofrodents,containstwopolyadenylation
signals in tandem and can undergo alternative polyadenyla-
tion to produce transcripts of approximately 2 or 6 kb [69].
We sought to investigate the role of the human tau
3
򸀠-UTR in regulating tau expression with the hope that a
deeper understanding of these regulatory mechanisms may
lead to the identification of novel therapeutic approaches
t ot r e a tA Da n do t h e rt a u o p a t h i e s[ 65]. First, the exact
sequences of the short and long tau transcripts resulting
from alternative polyadenylation were determined by 3
򸀠-
RACE (rapid amplification of cDNA ends) and found to be
254 and 4163 nucleotides long, respectively. These data were
used to clone the wild-type and short tau 3
򸀠-UTR sequences
into a luciferase reporter construct. A similar construct that
expressesonlythelongtau3
򸀠-UTRwasmadebymutatingthe
proximal tau polyadenylation signal in the wild-type tau 3
򸀠-
U T Rc o n s t r u c t ss ot h a tc l e a v a g ea sw e l la sp o l y a d e n y l a t i o n
does not occur at this site. Using these reporter constructs,
wefoundtha ttheexpressionoftheshortisoformconstructis
significantlyhigherthanthatofthelongisoformconstructin
bothSH-SY5YandM17Dneuroblastomacelllinesatthelevel
of both protein and mRNA. In general, the wild-type tau 3
򸀠-
UTR reporter, which contains both polyadenylation signals,
had intermediate expression levels. These results suggest that
the long form of the tau 3
򸀠-UTR contains cis-elements not
found in the short form that downregulate expression.
Since miRNAs often bind 3
򸀠-UTR and regulate gene
expression, we considered whether one or more miRNAs
m i g h tc o n t r i b u t et ot h ec o n t r o lo ft a ue x p r e s s i o n .U s i n ga
candidateapproach,wefoundthatmiR-34acouldspecifically
reduce reporter expression at both the mRNA and protein
levels, as mutation of the miR-34a binding seed region in the
tau3
򸀠-UTRpreventedtheknockdown.Importantly,miR-34a
could specifically reduce endogenous tau expression at both
the mRNA and protein levels in M17D cells. To determine
the ability of endogenous miRNAs to regulate endogenous
tau expression, we cotransfected locked nucleic acid (LNA)
miRNA inhibitors of miR-34a, -34b, and -34c into M17D
cells. We used a combination of LNA inhibitors of all miR-34
family members to prevent possible compensation by other
family members. Inhibition of endogenous miR-34 family
members led to a moderate increase in endogenous tau
protein expression, suggesting that these miRNAs do indeed
repress tau levels. In addition to the miR-34a binding site on
the tau 3
򸀠-UTR, other regions containing relevant cis-acting
elements were identified by inserting defined fragments into
t h el u c i f e r a s er e p o r t e rv e c t o r .Th u s ,m i R - 3 4 aa n dp e r h a p s
other miRNAs could in principle be used therapeutically to
reduce tau levels.
3. BACE1 mRNA
3.1. Antisense Strategies to Shift Alternative mRNA Splicing of
BACE1[70]. Thepre-mRNAofBACE1isalternativelyspliced
throughtheuseofalternativesplicesitesinexons3and4(see
Figure 7(a)). Normal splicing of BACE1 results in production
of the full-length 501-amino acid active protein (BACE1 501),
while alternative splicing of BACE1 results in production of
isoforms BACE1 476 (through use of the alternative exon
4s p l i c es i t e ) ,B A C E 14 5 7( t h r o u g hu s eo ft h ea l t e r n a t i v e
exon 3 splice site), or BACE1 432 (through use of both
alternative sites in exons 3 and 4). We carefully quantified
these alternatively spliced BACE1 transcripts in brain and
pancreas and identified a novel, albeit very minor, splice
variant of BACE1 as well (BACE1 455, with exon 4 completely
skipped) [70]. We found that the cellular environment can
affect BACE1 alternative splicing, as different cell types can
give different proportions of these splice variants. Contrary
to a previousreport[71],however,wedidnotfinddifferences
in BACE1 splice variants in different brain regions.
Molecular modeling of the BACE1 protein (for which
crystal structures are available [72]) suggested that the alter-
nativespliceisoformswouldhaveadisruptedstructure,asthe
deletedregionsappeartobecriticalpartsofthecorestructure
n e a rt h ea c t i v es i t e[ 70]( Figure 7(b)). Consistent with this
hypothesis, we found that isolated BACE1 proteins translated
from alternatively spliced transcripts have essentially no 𝗽-
secretase activity. While previous studies had examined A𝗽
productionincellstransfectedwithBACE1variants,isolation
of these variants was not carried out, leading to inconsistent
results [73–75]. Furthermore, promotion of BACE1 alterna-
tive splicing using ASOs directed to the normal splice sites
(red lines, Figure 7(a))s u b s t a n t i a l l yr e d u c e dA 𝗽 production
in cells. Total BACE1 mRNA levels were not altered by
treatment with these ASOs. These findings illustrate the
importanceofBACE1alternativesplicinginaffectingthelevel
of A𝗽 produced in cells and suggest that targeting regulation
of BACE1 alternative splicing is a potential therapeutic
strategy for reducing 𝗽-secretase activity.
3.2. Role of a G-Quadruplex Structure in BACE1 mRNA Splic-
ing [76]. We recently identified another cis-element within
the BACE1 mRNA, one that putatively folds up into a G-
quadruplex, in which G-rich stretches form four-stranded
structures consisting of square arrangements of guanines
stabilized by Hoogsteen hydrogen bonding and K+ chelation
(Figure 8)[ 77]. Four proximal GGG motifs are found within
exon 3, near the alternative 5
򸀠 splice site leading to BACE1
457 and another alternative site leading to a form with aScientifica 9
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Figure7:BACE1alternativesplicingandtargetingbyantisenseoligonucleotides.(a)Alternativesplicesitesinexons3and4ofBACE1mRNA.
The amino acid length of each isoform upon translation to protein is indicated. Red lines indicate antisense oligonucleotides targeted to the
normal5
򸀠 and3
򸀠 splicesites.(b)StructureofBACE1showingtheN-andC-terminallobes,withtheactivesiteattheinterface.Coloredregions
are parts of the full-length BACE1 enzyme that would be deleted in alternative splice isoforms. Note that these sites are in and around the
active site and would be expected to affect the folding and final conformation of the enzyme.
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Figure 8: Site of four successive GGG motifs in exon 3 of BACE1 mRNA and alternative splice sites. These motifs fold into a G-quadruplex
structure, with stacked sets of four planar guanine rings stabilized by Hoogsten base pairing and a K+ ion.
prematurestopcodonafter127aminoacids[75](B A CE1127)
(Figure 8).MutationofanyoftheseGGGmotifstoGAG(the
GGGG motif was mutated to GAAG) within a BACE1 exon
3–5minigeneconstructledtosubstantialincreasesinBACE1
457 and 432 splicing by qRT-PCR in HEK293 cells [76],
consistent with these motifs being part of a cis-element that
represses use of this alternative splice site. Little or no effect
wasseenonlevelsofBACE476(alternativeexon4splicesite)
or 455 (exon 4 skipped) splice isoforms. For most mutants, a
significant decrease in full-length BACE1 501 splice isoform
was also seen. Mutations in other minigene systems further
supportedtheimportanceofthesefourproximalGGGmotifs
in regulating the use of the alternative 5
򸀠 splice site in exon 3.
Forexample,placementoftheputativeBACE1G-quadruplex
motif into a 𝗽-globin minigene system near an alternative 5
򸀠
splice site is sufficient to cause exon skipping.
Nuclease protection assays, nuclear magnetic resonance,
and circular dichroism spectroscopy revealed that this 4
x GGG sequence indeed folds into a G-quadruplex struc-
ture stabilized by K+ ions [76]. Affinity pull-down using
biotinylated RNA of the BACE1 4 x GGG sequence led to
identification of several proteins capable of binding to the10 Scientifica
G-rich sequence, and one of these, heterogeneous nuclear
ribonucleoprotein H (hnRNP H), was found to regulate
BACE1exon3alternativesplicingandinamannerdependent
on the G-rich sequence. Knockdown of hnRNP H led to a
decrease in the full-length BACE1 mRNA isoform as well
as a decrease in A𝗽 production from APP, suggesting new
possibilities for therapeutic approaches to AD.
4. Outlook
The string of clinical failures of agents targeting proteins
involved in A𝗽 production as well as the inability to advance
agents targeting tau or tau-phosphorylating kinases argues
f o rt h ep u r s u i to fa l t e r n a t i v es t r a t e g i e sf o rA Dt h e r a p e u t i c s .
Herein, we have surveyed our recent work toward targeting
mRNA relevant to AD and FTLD-tau, specifically tau and
BACE1 mRNA.
For tau mRNA, we have validated a stem-loop structure
thatregulatesexon10splicing,therebycontrollingthecritical
4R/3R ratio implicated in FTLD-tau pathogenesis. With this
validated target, we screened for and identified a small
molecule, MTX, that binds to and stabilizes the stem-loop,
the opposite effect of FTLD-tau-causing mutations in this
region.WealsodesignedbipartiteASOsthatbindtheregions
that flank this stem-loop and showed that these can shift tau
splicing away from 4R tau and toward 3R tau. Attempts to
combineMTXandbipartiteASOstoformtripartite“molecu-
larclasps”weresuccessful,althoughfurthermodificationsare
needed to decrease cytotoxicity. We have also systematically
studied the tau mRNA 3
򸀠-UTR, identified regions within the
3
򸀠-UTR that are critical to regulating tau mRNA and protein
levels, and discovered that miR-34a reduces tau.
F o rB A C E 1m R N A ,w eh a v ev a l i d a t e di s o f o r m sr e s u l t i n g
from alternative splicing with exons 3 and 4 and demon-
strated that the proteins encoded by these alternative BACE1
mRNA splice isoforms have little or no proteolytic activity
for producing A𝗽.W i t ht h i sk n o w l e d g e ,w et e s t e dA S O s
targeting the normal splice sites leading to enzymatically
active, full-length BACE1 and found that these ASOs could
effectively shift splicing toward the inactive alternative iso-
forms and reduce A𝗽 production. We also discovered a G-
quadruplex structure within exon 3 of BACE1 mRNA that
c a nr e g u l a t eu s eo fa l t e r n a t i v es p l i c es i t e s ,a tl e a s ti np a r tb y
recruitment of hnRNP H. Perhaps agents targeting the G-
quadruplex or hnRNA H could likewise shift BACE1 mRNA
splicing and lower A𝗽 production.
Taken together, these results provide proof of principle
that targeting tau or BACE1 mRNA for potentially thera-
peutic ends is possible. However, much further work will
be needed before this early validation can be translated into
practical therapeutics for AD and FTLD-tau. Further details
are needed on the mechanisms by which these mRNAs
a r er e g u l a t e d .F o ri n s t a n c e ,w i t ht a u ,l i t t l ei sk n o w na b o u t
t r a n s - f a c t o r st h a ti n t e r a c tw i t ht h e3
򸀠-UTR. Although we
have discovered a role for miR-34a, other miRNAs may also
contribute and perhaps some much more substantially than
miR-34a. Protein trans-factors are also likely involved, some
ofwhichmaybemoredruggablethanthetaumRNA3
򸀠-UTR
itself.ForBACE1,otherregulatingproteinsbesideshnRNPH
a r el i k e l yi n v o l v e da n dc o u l db ed i s c o v e r e dt h r o u g ha ffi n i t y
isolation of other regions of the BACE1 mRNA besides the
G-quadruplex. For both tau and BACE1 mRNA, other struc-
tural motifs besides the stem-loop (tau) and G-quadruplex
(BACE1) are also likely to be present, and a systematic search
for such structures would be warranted.
Such basic understanding of tau and BACE1 mRNA
structureandfunctionmayrevealnewstrategiesfortargeting
these mRNAs for therapeutic purposes. Toward that end,
however, there is a great need to investigate new means
of discovering agents that bind RNA structures. This area
of chemical design is still in its infancy, and there are few
if any agents that target specific RNA structures. While
oligonucleotides such as ASOs, siRNAs, and miRNAs can
provide such specificity, these agents have poor drug-like
properties. Thus, another important avenue of investigation
isthedevelopmentofpracticaldeliverystrategiesofdesigned
oligonucleotidestothebrain.Thisisadauntingchallenge,but
effortsmustbemadegiventhestrongtherapeuticpotentialof
oligonucleotides and the lack of any effective therapeutics for
the devastating and widespread problems of AD and FTLD-
tau.
Conflict of Interests
The author declares that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
The author acknowledges the United States National Insti-
tutes of Health, the Alzheimer’s Association, and the
A l z h e i m e rD r u gD i s c o v e r yF o u n d a t i o nf o rg r a n ts u p p o r ti n
this area of research.
References
[1] C. A. Ross and M. A. Poirier, “Protein aggregation and neu-
rodegenerative disease,” Nature Medicine,v o l .1 0 ,s u p p l e m e n t ,
p p .S 1 0 – S 1 7 ,2 0 0 4 .
[2] M. Goedert and M. G. Spillantini, “A century of Alzheimer’s
disease,” Science,v o l .3 1 4 ,n o .5 8 0 0 ,p p .7 7 7 – 7 8 1 ,2 0 0 6 .
[3] R. E. Tanzi and L. Bertram, “Twenty years of the Alzheimer’s
diseaseamyloidhypothesis:ageneticperspective,”Cell,vol.120,
no. 4, pp. 545–555, 2005.
[4] I. Benilova, E. Karran, and B. de Strooper, “The toxic A𝗽
oligomer and Alzheimer’s disease: an emperor in need of
clothes,” Nature Neuroscience,v o l .1 5 ,n o .3 ,p p .3 4 9 – 3 5 7 ,2 0 1 2 .
[5] R. M. Koffie, M. Meyer-Luehmann, T. Hashimoto et al., “Oligo-
meric amyloid 𝗽 associates with postsynaptic densities and
correlates with excitatory synapse loss near senile plaques,”
Proceedings of the National Academy of Sciences of the United
States of America,v o l .1 0 6 ,n o .1 0 ,p p .4 0 1 2 – 4 0 1 7 ,2 0 0 9 .
[ 6 ]M .D .W e i n g a r t e n ,A .H .L o c k w o o d ,S .Y .H w o ,a n dM .W .
Kirschner,“Aproteinfactoressentialformicrotubuleassembly,”
Proceedings of the National Academy of Sciences of the United
States of America,v o l .7 2 ,n o .5 ,p p .1 8 5 8 – 1 8 6 2 ,1 9 7 5 .
[7] D. W. Cleveland, S. Y. Hwo, and M. W. Kirschner, “Purification
of tau, a microtubule associated protein that induces assemblyScientifica 11
of microtubules from purified tubulin,” Journal of Molecular
Biology,v o l .1 1 6 ,n o .2 ,p p .2 0 7 – 2 2 5 ,1 9 7 7 .
[8] A. Himmler, D. Drechsel, M. W. Kirschner, and D. W. Martin
Jr., “Tau consists of a set of proteins with repeated C-termi-
nal microtubule-binding domains and variable N-terminal
domains,”Molecular and Cellular Biology,v o l .9 ,n o .4,p p .138 1 –
1388, 1989.
[9] K. A. Butner and M. W. Kirschner, “Tau protein binds to
microtubules through a flexible array of distributed weak sites,”
The Journal of Cell Biology, vol. 115, no. 3, pp. 717–730, 1991.
[10] B.L.GoodeandS.C.Feinstein,“Identificationofanovelmicro-
tubule binding and assembly domain in the developmentally
regulatedinter-repeatregionoftau,”Th eJ o u rn a lo fCe l lB i o l ogy,
v o l .1 2 4 ,n o .5 ,p p .7 6 9 – 7 8 1 ,1 9 9 4 .
[11] C.Ballatore,V.M.-Y.Lee,andJ.Q.Trojanowski,“Tau-mediated
neurodegeneration in Alzheimer’s disease and related disor-
ders,” Nature Reviews Neuroscience,v o l .8 ,n o .9 ,p p .6 6 3 – 6 7 2 ,
2007.
[12] E. D. Roberson, K. Scearce-Levie, J. J. Palop et al., “Reducing
endogenous tau ameliorates amyloid 𝗽-induced deficits in an
Alzheimer’s disease mouse model,” Science,v o l .3 1 6 ,n o .5 8 2 5 ,
p p .7 5 0 – 7 5 4 ,2 0 0 7 .
[13] F. Clavaguera, T. Bolmont, R. A. Crowther et al., “Transmission
and spreading of tauopathy in transgenic mouse brain,” Nature
Cell Biology,v o l .1 1 ,n o .7 ,p p .9 0 9 – 9 1 3 ,2 0 0 9 .
[1 4] A.deCaligno n,M.P olydo r o ,M.S u´ arez-Calvetetal.,“Propaga-
tion of tau pathology in a model of early Alzheimer’s disease,”
Neuron,v o l .7 3 ,n o .4 ,p p .6 8 5 – 6 9 7 ,2 0 1 2 .
[15] L. Liu, V. Drouet, J. W. Wu et al., “Trans-synaptic spread of tau
pathology in vivo,” PLoS ONE,v o l .7 ,n o .2 ,A r t i c l eI De 3 1 3 0 2 ,
2012.
[16] V. M.-Y. Lee, M. Goedert, and J. Q. Trojanowski, “Neurodegen-
erative tauopathies,” Annual Review of Neuroscience,v o l .2 4,p p .
1121–1159, 2001.
[17] R. Rademakers, M. Neumann, and I. R. Mackenzie, “Advances
inunderstandingthemolecularbasisoffrontotemporaldemen-
tia,” Nature Reviews Neurology,v o l .8 ,n o .8 ,p p .4 2 3 – 4 3 4 ,2 0 1 2 .
[18] M.Hutton,C.L.Lendon,P.Rizzuetal.,“Associationofmissense
and 5
򸀠-splice-site mutations in tau with the inherited dementia
FTDP-17,” Nature,v o l .3 9 3 ,n o .6 6 8 6 ,p p .7 0 2 – 7 0 5 ,1 9 9 8 .
[19] M. G. Spillantini, J. R. Murrell, M. Goedert, M. R. Farlow, A.
Klug, and B. Ghetti, “Mutation in the tau gene in familial mul-
tiple system tauopathy with presenile dementia,” Proceedings of
theNationalAcademyofSciencesoftheUnitedStatesofAmerica,
v o l .9 5 ,n o .1 3 ,p p .7 7 3 7 – 7 7 4 1 ,1 9 9 8 .
[20] M.S.Wolfe,“Taumutationsinneurodegenerativediseases,”The
J o u r n a lo fB i o l o g i c a lC h e m i s t r y ,v o l .2 8 4 ,n o .1 0 ,p p .6 0 2 1 – 6 0 2 5 ,
2009.
[21] S. L. Cole and R. Vassar, “The role of amyloid precursor protein
processing by BACE1, the 𝗽-secretase, in Alzheimer disease
pathophysiology,” The Journal of Biological Chemistry,v o l .2 8 3 ,
n o .4 4 ,p p .2 9 6 2 1 – 2 9 6 2 5 ,2 0 0 8 .
[ 2 2 ]B .d eS t r o o p e r ,T .I w a t s u b o ,a n dM .S .W o l f e ,“ P r e s e n i l i n sa n d
gamma-secretase: structure, function, and role in Alzheimer
disease,” Cold Spring Harbor Perspectives in Medicine,v o l .2 ,n o .
1, Article ID a006304, 2012.
[23] A. K. Ghosh, S. Gemma, and J. Tang, “𝗽-secretase as a
therapeutic target for Alzheimer’s disease,” Neurotherapeutics,
vol. 5, no. 3, pp. 399–408, 2008.
[24] D. J. Selkoe and M. S. Wolfe, “Presenilin: running with scissors
in the membrane,” Cell,v o l .1 3 1 ,n o .2 ,p p .2 1 5 – 2 2 1 ,2 0 0 7 .
[25] R. Kopan and M. X. G. Ilagan, “𝗾-secretase: proteasome of the
membrane?” Nature Reviews Molecular Cell Biology,v o l .5 ,n o .
6, pp. 499–504, 2004.
[26] T. E. Golde, E. H. Koo, K. M. Felsenstein, B. A. Osborne, and
L. Miele, “gamma-secretase inhibitors and modulators,” Biochi-
mica et Biophysica Acta, vol. 1828, no. 12, pp. 2898–2907, 2013.
[27] D .Schenk,G.S.Basi,andM.N.P angalos,“T reatmentstrategies
targetingamyloidbeta-protein,”ColdSpringHarborPerspectives
in Medicine, vol. 2, no. 9, Article ID a006387, 2012.
[28] S. Salloway, R. Sperling, N. C. Fox et al., “Two phase 3 trials of
bapineuzumab in mild-to-moderate Alzheimer’s disease,” The
New England Journal of Medicine,v o l .3 7 0 ,p p .3 2 2 – 3 3 3 ,2 0 1 4 .
[29] R. S. Doody, R. G. Thomas, M. Farlow et al., “Phase 3 trials
ofsolanezumabformild-to-moderateAlzheimer’sdisease,”The
New England Journal of Medicine,v o l .3 7 0 ,p p .3 1 1 – 3 2 1 ,2 0 1 4 .
[30] V. Tell and A. Hilgeroth, “Recent developments of protein
kinase inhibitors as potential AD therapeutics,” Frontiers in
Cellular Neuroscience,v o l .7 ,a r t i c l e1 8 9 ,2 0 1 3 .
[31] G. V. W. Johnson and W. H. Stoothoff, “Tau phosphorylation in
neuronal cell function and dysfunction,” Journal of Cell Science,
v o l .1 1 7 ,n o .2 4 ,p p .5 7 2 1 – 5 7 2 9 ,2 0 0 4 .
[32] M. Goedert and R. Jakes, “Mutations causing neurodegener-
ative tauopathies,” Biochimica et Biophysica Acta—Molecular
Basis of Disease, vol. 1739, no. 2, pp. 240–250, 2005.
[33] D. J. Nicholl, M. A. Greenstone, C. E. Clarke et al., “An
englishkindredwithanovelrecessivetauopathyandrespiratory
failure,” Annals of Neurology,v o l .5 4 ,n o .5 ,p p .6 8 2 – 6 8 6 ,2 0 0 3 .
[34] A. Grover, H. Houlden, M. Baker et al., “5
򸀠 splice site mutations
i nt a ua s s o c i a t e dw i t ht h ei n h e r i t e dd e m e n t i aF T D P - 1 7a ff e c ta
stem-loop structure that regulates alternative splicing of exon
10,” Th eJ o u r n a lo fB i o l o g i c a lC h e m i s t r y ,v o l .2 7 4 ,n o .2 1 ,p p .
15134–15143, 1999.
[35] L. Varani, M. Hasegawa, M. G. Spillantini et al., “Structure of
tauexon10splicingregulatoryelementRNAanddestabilization
by mutations of frontotemporal dementia and parkinsonism
linked to chromosome 17,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 96, no. 14, pp.
8229–8234, 1999.
[36] C. P. Donahue, C. Muratore, J. Y. Wu, K. S. Kosik, and M. S.
Wolfe, “Stabilization of the tau exon 10 stem loop alters pre-
mRNA splicing,” Th eJ o u r n a lo fB i o l o g i c a lC h e m i s t r y ,v o l .2 8 1 ,
no. 33, pp. 23302–23306, 2006.
[37] Z.Jiang,J.Cote,J.M.K won,A.M.Goate,andJ.Y .W u,“ Aberrant
splicing of tau pre-mRNA caused by intronic mutations associ-
atedwiththeinheriteddementiafrontotemporaldementiawith
parkinsonismlinkedtochromosome17,”MolecularandCellular
Biology, vol. 20, no. 11, pp. 4036–4048, 2000.
[ 3 8 ]C .P .D o n a h u e ,J .N i ,E .R o z n e r s ,M .A .G l i c k s m a n ,a n dM .S .
Wolfe,“IdentificationoftaustemloopRNAstabilizers,”Journal
of Biomolecular Screening,v o l .1 2 ,n o .6 ,p p .7 8 9 – 7 9 9 ,2 0 0 7 .
[ 3 9 ]S .Z h e n g ,Y .C h e n ,C .P .D o n a h u e ,M .S .W o l f e ,a n dG .V a r a n i ,
“Structural basis for stabilization of the tau pre-mRNA splicing
regulatory element by novantrone (mitoxantrone),” Chemistry
and Biology,v o l .1 6 ,n o .5 ,p p .5 5 7 – 5 6 6 ,2 0 0 9 .
[40] L.Yang,E.Peacey,J.Dicksonetal.,“Mitoxantroneanaloguesas
ligands for a stem-loop structure of tau pre-mRNA,” Journal of
Medicinal Chemistry, vol. 52, no. 21, pp. 6523–6526, 2009.
[ 4 1 ]N .S e r g e a n t ,A .W a t t e z ,a n dA .D e l a c o u r t e ,“ N e u r o fi b r i l l a r y
degenerationinprogressivesupranuclearpalsyandcorticobasal
degeneration: tau pathologies with exclusively “exon 10” iso-
forms,” Journal of Neurochemistry,v o l .7 2 ,n o .3 ,p p .1 2 4 3 – 1 2 4 9 ,
1999.12 Scientifica
[42] M. Ingelsson, K. Ramasamy, I. Cantuti-Castelvetri et al., “No
alteration in tau exon 10 alternative splicing in tangle-bearing
neurons of the Alzheimer’s disease brain,” Acta Neuropatholog-
ica,v o l .1 1 2 ,n o .4 ,p p .4 3 9 – 4 4 9 ,2 0 0 6 .
[43] C. Conrad, J. Zhu, C. Conrad et al., “Single molecule profiling
of tau gene expression in Alzheimer’s disease,” Journal of
Neurochemistry,v o l .1 0 3 ,n o .3 ,p p .1 2 2 8 – 1 2 3 6 ,2 0 0 7 .
[44] M. von Bergen, S. Barghorn, J. Biernat, E.-M. Mandelkow, and
E. Mandelkow, “Tau aggregation is driven by a transition from
random coil to beta sheet structure,” Biochimica et Biophysica
Acta—Molecular Basis of Disease,v o l .1 7 3 9 ,n o .2 ,p p .1 5 8 – 1 6 6 ,
2005.
[45] L. Varani, M. G. Spillantini, M. Goedert, and G. Varani, “Stru-
ctural basis for recognition of the RNA major groove in the
tau exon 10 splicing regulatory element by aminoglycoside
antibiotics,” Nucleic Acids Research,v o l .2 8 ,n o .3 ,p p .7 1 0 – 7 1 9 ,
2000.
[46] E. Peacey, L. Rodriguez, Y. Liu, and M. S. Wolfe, “Targeting a
pre-mRNA structure with bipartite antisense molecules modu-
latestaualternativesplicing,”NucleicAcidsResearch,vol.40,no .
19, pp. 9836–9849, 2012.
[ 4 7 ]E .U h l m a n n ,A .P e y m a n ,G .B r e i p o h l ,a n dD .W .W i l l ,“ P N A :
synthetic polyamide nucleic acids with unusual binding prop-
erties,”AngewandteChemieInternationalEdition,vol.37 ,no .20,
pp. 2797–2823, 1998.
[48] K. Albertshofer, A. M. Siwkowski, E. V. Wancewicz et al., “Stru-
cture-activity relationship study on a simple cationic peptide
motif for cellular delivery of antisense peptide nucleic acid,”
Journal of Medicinal Chemistry,v o l .4 8 ,n o .2 1 ,p p .6 7 4 1 – 6 7 4 9 ,
2005.
[49] C. F. Bennett and E. E. Swayze, “RNA targeting therapeu-
tics: molecular mechanisms of antisense oligonucleotides as
at h e r a p e u t i cp l a t f o r m , ”Annual Review of Pharmacology and
Toxicology,v o l .5 0 ,p p .2 5 9 – 2 9 3 ,2 0 1 0 .
[50] Y. Liu, L. Rodriguez, and M. S. Wolfe, “Template-directed
synthesis of a small molecule-antisense conjugate targeting an
mRNA structure,” Bioorganic Chemistry, vol. 54, pp. 7–11, 2014.
[51] K.R.Hande,“Clinicalapplicationsofanticancerdrugstargeted
to topoisomerase II,” Biochimica et Biophysica Acta,v o l .1 4 0 0 ,
no. 1–3, pp. 173–184, 1998.
[52] J. R. Thomas and P.J. Hergenrother, “Targeting RNA with small
molecules,” Chemical Reviews,v o l .1 0 8 ,n o .4 ,p p .1 1 7 1 – 1 2 2 4 ,
2008.
[ 5 3 ]A .E .S p e e r s ,G .C .A d a m ,a n dB .F .C r a v a t t ,“ A c t i v i t y - b a s e d
protein profiling in vivo using a copper(I)-catalyzed azide-
alkyne [3 + 2] cycloaddition,” Journal of the American Chemical
Society,v o l .1 2 5 ,n o .1 6 ,p p .4 6 8 6 – 4 6 8 7 ,2 0 0 3 .
[ 5 4 ]P .V .C h a n g a ,J .A .P r e s c h e r a ,E .M .S l e t t e ne ta l . ,“ C o p p e r - f r e e
click chemistry in living animals,” Proceedings of the National
Academy of Sciences of the United States of America,v o l .1 0 7 ,n o .
5, pp. 1821–1826, 2010.
[55] A. E. Speers and B. F. Cravatt, “Profiling enzyme activities in
vivousingclickchemistrymethods,”ChemistryandBiology,vol.
11, no. 4, pp. 535–546, 2004.
[56] M. Whiting, J. Muldoon, Y.-C. Lin et al., “Inhibitors of HIV-1
protease by using in situ click chemistry,” Angewandte Chemie
International Edition,v o l .4 5 ,n o .9 ,p p .1 4 3 5 – 1 4 3 9 ,2 0 0 6 .
[57] W. G. Lewis, L. G. Green, F. Grynszpan et al., “Click chemistry
in situ: acetylcholinesterase as a reaction vessel for the selective
assembly of a femtomolar inhibitor from an array of building
blocks,” Angewandte Chemie International Edition,v o l .4 1 ,n o .
6, pp. 1053–1057, 2002.
[58] R. Manetsch, A. Krasi´ n s k i ,Z .R a d i ´ c et al., “In situ click
chemistry:enzymeinhibitorsmadetotheirownspecifications,”
Journal of the American Chemical Society,v o l .1 2 6 ,n o .4 0 ,p p .
12809–12818, 2004.
[59] V. P. Mocharla, B. Colasson, L. V. Lee et al., “In situ click
chemistry: enzyme-generated inhibitors of carbonic anhydrase
II,” Angewandte Chemie International Edition,v o l .4 4 ,n o .1 ,p p .
116–120, 2004.
[60] A. Krasi´ nski, Z. Radi´ c, R. Manetsch et al., “In situ selection of
leadcompoundsbyclickchemistry:target-guidedoptimization
of acetylcholinesterase inhibitors,” Journal of the American
Chemical Society,v o l .1 2 7 ,n o .1 8 ,p p .6 6 8 6 – 6 6 9 2 ,2 0 0 5 .
[61] A. T. Poulin-Kerstein and P. B. Dervan, “DNA-Templated
Dimerization of Hairpin Polyamides,” Journal of the American
Chemical Society,v o l .1 2 5 ,n o .5 1 ,p p .1 5 8 1 1 – 1 5 8 2 1 ,2 0 0 3 .
[ 6 2 ]R .K u m a r ,A .E l - S a g h e e r ,J .T u m p a n e ,P .L i n c o l n ,L .M .W i l -
helmsson, and T. Brown, “Template-directed oligonucleotide
strand ligation, covalent intramolecular DNA circularization
and catenation using click chemistry,” Journal of the American
Chemical Society,v o l .1 2 9 ,n o .2 1 ,p p .6 8 5 9 – 6 8 6 4 ,2 0 0 7 .
[63] N.Kashiwagi,K.Yamashita,H.Furuta,andY.Ikawa,“Designed
RNAs with two peptide-binding units as artificial templates
for native chemical ligation of RNA-binding peptides,” Chem-
BioChem,v o l .1 0 ,n o .1 7 ,p p .2 7 4 5 – 2 7 5 2 ,2 0 0 9 .
[ 6 4 ]Y .X u ,Y .S u z u k i ,a n dM .K o m i y a m a ,“ C l i c kc h e m i s t r yf o rt h e
identification of g-quadruplex structures: discovery of a DNA-
RNA g-quadruplex,” Angewandte Chemie International Edition,
v o l .4 8 ,n o .1 8 ,p p .3 2 8 1 – 3 2 8 4 ,2 0 0 9 .
[65] J. R. Dickson, C. Kruse, D. R. Montagna, B. Finsen, and
M. S. Wolfe, “Alternative polyadenylation and miR-34 family
members regulate tau expression,” Journal of Neurochemistry,
vol. 127, no. 6, pp. 739–749, 2013.
[66] L. W. Barrett, S. Fletcher, and S. D. Wilton, “Regulation of
eukaryotic gene expression by the untranslated gene regions
and other non-coding elements,” Cellular and Molecular Life
Sciences,v o l .6 9 ,n o .2 1 ,p p .3 6 1 3 – 3 6 3 4 ,2 0 1 2 .
[67] J.-M. Chen, C. F´ erec, and D. N. Cooper, “A systematic analysis
of disease-associated variants in the 3
򸀠 regulatory regions
of human protein-coding genes I: general principles and
overview,” Human Genetics,v o l .1 2 0 ,n o .1 ,p p .1 – 2 1 ,2 0 0 6 .
[68] Y. Shi, “Alternative polyadenylation: new insights from global
analyses,” RNA,v o l .1 8 ,n o .1 2 ,p p .2 1 0 5 – 2 1 1 7 ,2 0 1 2 .
[69] P. Poorkaj, A. Kas, I. D’Souza et al., “A genomic sequence anal-
ysis of the mouse and human microtubule-associated protein
tau,” Mammalian Genome,v o l .1 2 ,n o .9 ,p p .7 0 0 – 7 1 2 ,2 0 0 1 .
[ 7 0 ]K .R .M o w r e ra n dM .S .W o l f e ,“ P r o m o t i o no fB A C E 1m R N A
alternativesplicingreducesamyloid𝗽-peptideproduction,”The
J ournalofBiologicalChemistry,vol.283,no .27 ,pp .18694–18701,
2008.
[71] O. Zohar, S. Cavallaro, V. D’Agata, and D. L. Alkon, “Quantifi-
cationanddistributionof𝗽-secr eta seal t ern a ti v es p liceva ria n ts
in the rat and human brain,” Molecular Brain Research, vol. 115,
no. 1, pp. 63–68, 2003.
[72] L. Hong, G. Koelsch, X. Lin et al., “Structure of the protease
domainofmemapsin2(𝗽-secretase)complexedwithinhibitor,”
Science,v o l .2 9 0 ,n o .5 4 8 9 ,p p .1 5 0 – 1 5 3 ,2 0 0 0 .
[73] U. Bodendorf, F. Fischer, D. Bodian, G. Multhaup, and P. Paga-
netti, “A splice variant of 𝗽-secretase deficient in the amyloido-
genic processing of the amyloid precursor protein,” The Journal
of Biological Chemistry,v o l .2 7 6 ,n o .1 5 ,p p .1 2 0 1 9 – 1 2 0 2 3 ,2 0 0 1 .Scientifica 13
[74] R. Ehehalt, B. Michel, D. de Pietri Tonelli, D. Zacchetti, K.
Simons,andP.Keller,“Splicevariantsofthe𝗽-siteAPP-cleaving
enzyme BACE1 in human brain and pancreas,” Biochemical and
Biophysical Research Communications,v o l .2 9 3 ,n o .1 ,p p .30 – 3 7 ,
2002.
[75] H. Tanahashi and T. Tabira, “Three novel alternatively spliced
isoforms of the human beta-site amyloid precursor protein
cleaving enzyme (BACE) and their effect on amyloid beta-
peptide production,” Neuroscience Letters,v o l .3 0 7 ,n o .1 ,p p .9 –
12, 2001.
[76] J.-F.Fisette,D.R.Montagna,M.-R.Mihailescu,andM.S.Wolfe,
“A G-Rich element forms a G-quadruplex and regulates BACE1
mRNA alternative splicing,” Journal of Neurochemistry,v o l .1 2 1 ,
no. 5, pp. 763–773, 2012.
[77] S. Balasubramanian and S. Neidle, “G-quadruplex nucleic acids
as therapeutic targets,” Current Opinion in Chemical Biology,
vol. 13, no. 3, pp. 345–353, 2009.